A Phase II Trial of PD-1 Knockout Engineered T Cells for the Treatment of Advanced Lung Squamous Carcinoma progressed after multi-line treatment

Trial Profile

A Phase II Trial of PD-1 Knockout Engineered T Cells for the Treatment of Advanced Lung Squamous Carcinoma progressed after multi-line treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jan 2017

At a glance

  • Drugs PD-1 knockout T-cells (Primary)
  • Indications Carcinoma; Lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top